A 38-year-old woman with asthma is prescribed salbutamol (albuterol) 2 puffs every 4 hours for persistent symptoms. After 3 weeks, she reports diminishing relief with each dose and now requires the inhaler every 2 hours. Spirometry shows no change in baseline FEV₁. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient demonstrates **β₂-adrenergic receptor desensitization** (also called tachyphylaxis): progressive loss of bronchodilator response despite continued or increasing salbutamol use. This occurs with frequent, continuous β₂-agonist stimulation without concurrent anti-inflammatory therapy. ## Pharmacodynamic Mechanism of Desensitization **Key Point:** Continuous β₂-agonist exposure triggers: 1. **Receptor phosphorylation** by G-protein receptor kinase (GRK) → uncoupling from G-protein 2. **β-arrestin binding** → receptor internalization 3. **Downregulation** of receptor density on airway smooth muscle 4. **Loss of cAMP response** → diminished bronchodilation **High-Yield:** Desensitization is **reversible** with cessation of the agonist (24–48 hours) but **preventable** by concurrent anti-inflammatory therapy (inhaled corticosteroids), which suppresses GRK expression and stabilizes receptor function. ## Why Salbutamol Monotherapy Fails ```mermaid flowchart TD A["Frequent salbutamol use (every 2–4 hrs)"]:::outcome --> B["Continuous β₂ stimulation"]:::action B --> C["GRK phosphorylates β₂ receptor"]:::action C --> D["β-arrestin binding & internalization"]:::action D --> E["Receptor downregulation"]:::action E --> F["Loss of cAMP signalling"]:::action F --> G["Tachyphylaxis: ↓ bronchodilation"]:::urgent G --> H{"Add ICS?"}:::decision H -->|"Yes"| I["ICS suppresses GRK → restores sensitivity"]:::action H -->|"No"| J["Desensitization worsens"]:::urgent ``` ## Management Strategy | Approach | Mechanism | Outcome | |----------|-----------|----------| | **Increase salbutamol dose** | Overwhelms desensitized receptors | Worsens tachyphylaxis; no durable relief | | **Add LABA without ICS** | LABA is also a β₂-agonist | Exacerbates desensitization | | **Add ICS; discontinue frequent SABA** | ICS ↓ GRK; allows receptor recovery | ✓ Restores β₂ sensitivity; controls inflammation | | **Switch to anticholinergic (ipratropium)** | Different receptor (M₃) | Provides some bronchodilation but does not address underlying inflammation or receptor desensitization | **Clinical Pearl:** The presence of **persistent symptoms despite escalating salbutamol use** + **normal baseline FEV₁** is the classic presentation of SABA overuse and desensitization. This is a **red flag for inadequate anti-inflammatory therapy**. **Mnemonic — Desensitization Prevention (DIP):** - **D**iscontinue frequent SABA monotherapy - **I**nhaled Corticosteroid (ICS) is mandatory - **P**reserve SABA for acute relief only (as-needed, <2 days/week) [cite:Harrison 21e Ch 314; KD Tripathi 8e Ch 27]